ERBB2 and breast cancer: In BC, an enrichment in TIL-B is a favorable prognostic factor [146,174,289,290,291,292,293], particularly when located inside cancer islands [294], and is associated with higher response rates to CT [295,296,297], anti-HER2 agents [298] in HER2+ BC, and ICIs in eTNBC [83,207].